241 results about "Buffered phosphate" patented technology

Methods of enhancing fluid flow through a vascular site occupied by a vascular occlusion, as well as systems and kits for use in practicing the same, are provided. In practicing the subject methods, the vascular site is flushed simultaneously with a first dissolution fluid (e.g., an organic matter dissolution fluid and / or an inorganic matter dissolution fluid), and a second dissolution fluid attenuating fluid, where flushing is carried out in a manner such that only a surface of the vascular occlusion is contacted with the non-attenuated dissolution fluid. Examples of dissolution fluid / dissolution fluid attenuating fluid pairs include: (1) oxidizing agent fluid and fluid comprising oxidizable neutralizing agent; (2) surfactant fluid and phosphate buffered saline; (3) acidic solution and phosphate buffered saline; etc. Flushing is carried out in this manner for a period of time sufficient for fluid flow through the vascular site to be enhanced, e.g. increased or established. The subject methods, systems and kits for practicing the same find use in the treatment of a variety of different vascular diseases characterized by the presence of vascular occlusions, including both partial and total occlusions.

Methods of enhancing fluid flow through a vascular site occupied by a vascular occlusion, as well as systems and kits for use in practicing the same, are provided. In practicing the subject methods, the vascular site is flushed simultaneously with a first dissolution fluid (e.g., an organic matter dissolution fluid and / or an inorganic matter dissolution fluid), and a second dissolution fluid attenuating fluid, where flushing is carried out in a manner such that only a surface of the vascular occlusion is contacted with the non-attenuated dissolution fluid. Examples of dissolution fluid / dissolution fluid attenuating fluid pairs include: (1) oxidizing agent fluid and fluid comprising oxidizable neutralizing agent; (2) surfactant fluid and phosphate buffered saline; (3) acidic solution and phosphate buffered saline; etc. Flushing is carried out in this manner for a period of time sufficient for fluid flow through the vascular site to be enhanced, e.g. increased or established. The subject methods, systems and kits for practicing the same find use in the treatment of a variety of different vascular diseases characterized by the presence of vascular occlusions, including both partial and total occlusions.

A method for processing biological tissue used in biological prostheses includes providing a tissue procurement solution formed from a phosphate buffered saline (PBS) solution and a chelating agent. The tissue is transferred from the tissue procurement solution and undergoes chemical fixation. The fixed tissue is then immersed in a series of fresh bioburden reduction process (BRP) solutions to extract phospholipids. The tissue procurement solution reduces the bioburden on the stored tissue and preserves tissue architecture by minimizing tissue swelling. The tissue procurement solution further reduces calcium from the incoming water and / or tissue, and inhibits enzymes that digest the collagen matrix. The serial immersion of the tissue in the fresh bioburden solutions ensures optimal extraction of phospholipids thereby mitigating subsequent calcification of the tissue.

A method for processing biological tissue used in biological prostheses includes providing a tissue procurement solution formed from a phosphate buffered saline (PBS) solution and a chelating agent. The tissue is transferred from the tissue procurement solution and undergoes chemical fixation. The fixed tissue is then immersed in a series of fresh bioburden reduction process (BRP) solutions to extract phospholipids. The tissue procurement solution reduces the bioburden on the stored tissue and preserves tissue architecture by minimizing tissue swelling. The tissue procurement solution further reduces calcium from the incoming water and / or tissue, and inhibits enzymes that digest the collagen matrix. The serial immersion of the tissue in the fresh bioburden solutions ensures optimal extraction of phospholipids thereby mitigating subsequent calcification of the tissue.

This invention provides an embolization material used for blocking a blood vessel in vivo for stopping the blood flow. The most suitable embolization material has a water swelling ratio of 30% or more, is degradable in a phosphate buffered saline, is formed as virtually spherical particles, and is preferably composed of a water insoluble poly(ethylene glycol) copolymer, wherein when the film formed from said polymer is saturated with water, it has an elastic modulus in tension of 1500 MPa or less. The embolization material of this invention can reliably block a blood vessel at an intended site without causing cohesion or clogging in a catheter or in the blood vessel at other than the intended site. Thereafter, the blocked site concerned can be liberated from the embolized state by degradation, and the degraded components can be metabolized or excreted outside the body.

Methods of enhancing fluid flow through a vascular site occupied by a vascular occlusion, as well as systems and kits for use in practicing the same, are provided. In practicing the subject methods, the vascular site is flushed simultaneously with a first dissolution fluid (e.g., an organic matter dissolution fluid and / or an inorganic matter dissolution fluid), and a second dissolution fluid attenuating fluid, where flushing is carried out in a manner such that only a surface of the vascular occlusion is contacted with the non-attenuated dissolution fluid. Examples of dissolution fluid / dissolution fluid attenuating fluid pairs include: (1) oxidizing agent fluid and fluid comprising oxidizable neutralizing agent; (2) surfactant fluid and phosphate buffered saline; (3) acidic solution and phosphate buffered saline; etc. Flushing is carried out in this manner for a period of time sufficient for fluid flow through the vascular site to be enhanced, e.g. increased or established. The subject methods, systems and kits for practicing the same find use in the treatment of a variety of different vascular diseases characterized by the presence of vascular occlusions, including both partial and total occlusions.

Improved efficacy in treatment of gastric disorders with botulinum toxin is obtained using liposomal encapsulated botulinum formulations for topical administration of the botulinum toxin. The liposomes are typically administered in a physiologically acceptable carrier such as saline or phosphate buffered saline by application onto the surface of the tissue within into the gastrointestinal (GI) tract in need of treatment. Preferably, the formulation is applied via a roller, sponge or nozzle that is attached to an endoscope.

The invention discloses a preparation method of a natural-tissue-derived decellularized and decalcified bone material. According to the method, any bone tissue of a mammal is treated with a protease inhibitor-containing normal saline buffer, an organic solvent, Tirton X-containing PBS (phosphate buffer saline), SDS (sodium dodecyl sulfonate)-containing PBS, pancreatin-containing PBS, deoxyribonuclease-containing PBS, an EDTA (ethylene diamine tetraacetic acid) isotonic solution and ultrasonic waves, and the decellularized and decalcified bone material is obtained. Cancellous bones and cortical bones can be decellularized completely and simultaneously, the conditions are mild, damage to an ECM (extracellular matrix) is avoided, rapidness and stability are realized, and the obtained decellularized and decalcified bone material has the advantages of good biocompatibility, high plasticity, high biomechanical strength and the like and can be used for clinically repairing bone regeneration and repair disorder such as bone defects, nonunion and the like caused by various causes.

The invention discloses an in-vitro culture method of NK (natural killer) cells and belongs to culture of human cells. The in-vitro culture method disclosed by the invention comprises the following steps: merging herceptin diluted by PBS (phosphate buffered saline) and human immunoglobulin diluted by the PBS, then uniformly and fully spreading at the bottom of a culture bottle and standing overnight; additionally taking peripheral blood, performing density gradient centrifugation, sucking a single nuclear cell, adding into a serum-free culture medium, and adjusting the concentration of the cells to 1.0*10<6> / ml-3.0*10<6> / ml; and then adding cell factors IL-2 and IL-15, adding into the culture bottle coated by the herceptin and culturing in an incubator. Therefore, on the basis of ensuring the amplification multiple of various cell subgroups, the growth and the proliferation of the NK cells are promoted, the killing activity of lymphocytes is enhanced, the serum-free culture medium can replace a serum-containing complete culture medium, the number of obtained culture products is equivalent to the activity of the cells, the in-vitro large-scale culture of the NK cells is realized, the in-vitro culture method is used for clinical biological treatment of the NK cells, and the safety in clinical application can be increased by using the in-vitro culture method.

A method for producing surfactant-stabilized microcapsules or nanocapsules including the steps of (a) preparing a suspension comprising a non-ionic sorbitan detergent and a salt in phosphate buffered saline; (b) adding to the suspension a nonionic polyoxyethylenesorbitan detergent to produce a solution; (c) heating while stirring the solution of step (b) to 55±5° C. and maintaining the temperature of the solution at 55±5° C. for several minutes; (d) allowing the solution to cool to room temperature; (e) autoclaving the solution; (f) creating surfactant-stabilized microbubbles and nanobubbles in the solution; and (g) collecting surfactant-stabilized nanocapsules and microcapsules formed from the microbubbles and nanobubbles.

The invention relates to a primary separation and culture method of human amniotic mesenchymal stem cells. The primary separation and culture method of the human amniotic mesenchymal stem cells comprises the following steps of: providing a human amniotic tissue, washing with PBS (phosphate buffer saline), shearing into pieces, adding 0.1-0.3% (by mass) trypsinase to digest, adding I-type collagenase and basal high-glucose DMEM until the final concentration of the I-type collagenase is 0.1-0.2%, digesting, separating the digested human amniotic tissue centrifugally to obtain a precipitate, resuspending the precipitate with PBS, filtering, separating centrifugally, and removing the supernatant to obtain the human amniotic mesenchymal stem cells. Compared with the prior art, the primary separation and culture method provided by the invention has the advantages that because a small amount of trypsinase is used to pretreat and loosen the human amniotic tissue, and further the I-type collagenase with good tissue specificity is used to treat the human amniotic tissue, the digesting time can be shortened greatly, the primary separation steps can be simplified, the human amniotic mesenchymal stem cells can be obtained at a high yield, and the viability of the obtained human amniotic mesenchymal stem cells can be improved greatly compared with that of the human amniotic mesenchymal stem cells in the prior art.

The invention relates to a micelle based on non-linear polyethylene glycol-polylactic acid block copolymer and a preparation method thereof. The preparation method comprises the following steps: using a single-end hydroxyl or a double-end-group modified polyethylene glycol to induce lactide for ring-opening polymerization, thereby obtaining a non-linear spindle polyethylene glycol-polylactic acid block copolymer, and then obtaining a micron-sized spindle micelle with high stability through self-assembly in aqueous solution. The particle sizes can be controlled through adjusting the molecular weights of polyethylene glycol and the polylactic acid, the critical micelle concentration is as high as 3.72*10-4g / L, and the drug loading rate and the drug encapsulation rate of the micelle are respectively up to 39.9 percent and 70.8 percent by mass percent, superior to a spherical micelle formed through assembly of a linear polyethylene glycol-polylactic acid block copolymer with an identical molecular weight. Simultaneously, the micelle coated with oil-soluble drugs demonstrates controllable release properties to drug molecules in phosphate buffer saline with the pH value of 7.4. The micelle can be used for slow release and targeted delivery of drugs, enhancement of drug effects and the like.

The invention provides a preparation method of a determination kit for triazophos chemoluminescence immunoassay and relates to determination kits for triazophos chemoluminescence immunoassay and a preparation method and a using method thereof. The invention solves the technical problem of high minimum detection limit in the conventional direct competitive enzyme-linked immunosorbent assay method. The determination kit for triazophos chemoluminescence immunoassay consists of a triazophos standard substance, a carrier coating a triazophos monoclonal antibody, horse radish peroxidase-labeled triazophos hapten, a chemiluminescent sensitizing solution and phosphate buffer saline (PBS). The kit is prepared by putting the prepared triazophos standard substance, the carrier coating the triazophos monoclonal antibody, the chemiluminescent sensitizing solution and the PBS buffer solution into a box to obtain the determination kit. When the kit is used, the triazophosstandard substance and samples are added into carrier reactive pores respectively and washed, and the chemiluminescent sensitizing solution is added, then the luminescent intensity is determined and specification curve is drawn, and finally the concentration of triazophos in the sample is determined. The minimum detection limit of triazophos is 0.06ng / mL, so the invention can be used in the field of foods.

The invention relates to a method for extracting high-molecular-weight genome from animal feces. The method comprises the steps of sample treatment, bacterial cell lysis and extraction of DNA (Deoxyribonucleic Acid). Specifically, the method comprises the steps of: dissolving an animal feces sample with aseptic PBS (Phosphate Buffered Saline) buffer, carrying out low-speed centrifuging and filtering to remove food residues in the feces, collecting bacterial cells, performing wall breaking on the bacteria by adopting lysozyme, decolorizing peptidase, protease and SDS (Sodium Dodecyl Sulfate), extracting with a mixture of phenol, chloroform and isoamyl alcohol as well as a mixture of chloroform and isoamyl alcohol, precipitating with isopropanol and sodium acetate, washing and drying, dissolving, and digesting RNA (Ribonucleic Acid) with RNAse (Ribonuclease). According to the invention, the method is simple in operation; and the DNA molecular weight of the extracted genome achieves more than 40kb, so that the researches on microorganism molecule ecological diversity, molecular identification, target gene amplification, macro genome library construction and the like are met.

The invention discloses a preparation method of angiogenesis-facilitating temperature-sensitive hydrogel. The preparation method comprises the following steps: under an ice-bath condition, adding the temperature-sensitive hydrogel powder provided by the invention and used as a raw material into a precooled PBS (phosphate buffer saline) solution, distilled water or DMEM (dulbecco's modified eagle medium), wherein the ratio of the temperature-sensitive hydrogel powder to the precooled PBS solution, distilled water or DMEM is 30mg:1ml, uniformly stirring, and placing the mixture in an environment with the temperature of 37 DEG C, so as to obtain the angiogenesis-facilitating temperature-sensitive hydrogel. The invention further discloses novel temperature-sensitive hydrogel powder and a preparation method thereof. The temperature-sensitive hydrogel powder can be stored for a long time at room temperature, the sterilization method for the temperature-sensitive hydrogel powder is simple, and the temperature-sensitive hydrogel powder can be conveniently produced in a large-scale manner and put into a market; the temperature-sensitive hydrogel prepared from the temperature-sensitive hydrogel powder has good temperature sensitiveness and biocompatibility, can be degraded in a body, has an angiogenesis-facilitating effect, and has a good application prospect in regenerative medicine and clinical treatment.

The invention discloses a method for detecting whitening efficacy of melothria heterophylla root extracts and relates to natural melothria heterophylla root extracts. The method comprises the following steps: (1) preparing a tyrosinase solution, an L-tyrosine solution and a PBS (phosphate buffer saline) solution as base solutions, then preparing four to-be-detected solutions, namely an arbutin solution, a supercritical CO2 extracted melothria heterophylla root extract solution, a water extracted melothria heterophylla root extract solution and an alcohol extracted melothria heterophylla root extract solution, quantitatively adding each base solution and one of the four to-be-detected solutions in four test tubes and shaking the solutions to be uniform; (2) heating the four test tubes in a water bath kettle, respectively determining the absorbance of each solution in each test tube under a wave length of 475nm and calculating the inhibition ratio of the to-be-detected solution with the concentration to tyrosinase; and (3) repeating the steps (1) and (2), determining the inhibition ratio of the other to-be-detected solutions to tyrosinase, determining the inhibition ratio of the other to-be-detected solutions with different concentrations to tyrosinase, and then according to the comparison of determination results, obtaining the whitening efficacy of each melothria heterophylla root extract and arbutin under the same concentration as well as the whitening efficacy of each melothria heterophylla root extract or arbutin under different concentrations.

Improved efficacy in treatment of rhinitis with botulinum toxin is obtained using liposomal encapsulated botulinum formulations for administration of the botulinum toxin. The liposomes are typically administered in a physiologically acceptable carrier such as saline or phosphate buffered saline by instillation into the nasal passages.

A porous body comprising apatite / collagen composite fibers, which has a half-value period of strength of 0.8-1.6 hours, the half-value period of strength being the time until the strength of the porous body of 10 mm×10 mm×4 mm comprising apatite / collagen composite fibers is reduced to half, after the porous body degassed by pressure reduction to 3 kPa (absolute pressure) for 10 minutes in a phosphate buffer saline is given a 20-% strain at a speed of 10 mm / minute.

The invention discloses a method for separating MVs (microvesicles) and MV exosomes from a tumor cell supernatant. The method comprises the following steps: after adherent culture of tumor cells, a culture solution is taken and subjected to centrifugation, the supernatant is mixed with a coupling compound, the mixture is incubated at 4 DEG C under the 100-300-rpm horizontal vibration condition for 3-16 h, a liquid is removed, an incubated coupling compound is obtained and cleaned with PBS (phosphate buffered saline), and coupling microspheres with MVs adsorbed are obtained. The total MVs extracted with the method retain the structures and components of all the MVs, and the yield is high. Secondary sorting can be performed, specific MVs can be analyzed, and the extraction efficiency and the research value are increased. The total extraction time requires only at least 4 hours to finish purification of the MVs and requires only at least 5 hours to finish purification of the exosomes. The extraction purity is higher, and experiments show that the extracted MVs account for 90% or higher of the total extracted proteins while organic precipitate accounts for lower than 20%.

The invention provides a test method for induced differentiating human embryo stem cells to retina pigment epithelial cells, which comprises the following steps that: A) 0.25% pancreatic enzyme and 0.1mg / mL collagenase iv are mixed into phosphate buffered saline (PBS) solution containing 1mM calcium chloride (CaCl2) and 20% KSR, the solution is used for digesting embryo stem (ES) clones, so the ES becomes an ES cell group with 5 to 10 cells; B) the ES clone is incubated in a culture dish which is wrapped by gelatin in a short time so as to remove the feeder layer cells; and C) the ES cell group is cultured in a continuous differential culture medium with the concentration of 6.7*102 cell groups per liters in a non-adhesive bacteria culture dish. The test method has the advantages such as simple and convenient method, good repeatability, high successful rate, good omnisexuality, rich and economical source and the like.

A multipurpose lens care solution comprising 0.005 wt. % to 1 wt. % of an anionic biopolymer, and an antimicrobial agent selected from 0.5 ppm to 2 ppm of poly(hexamethylene biguanide), 0.5 ppm to 2 ppm polyquaternium-1, or 1 ppm to 4 ppm alexidine. The lens care solution exhibits a ZO-1 immunostaining of HCEpiC similar to phosphate buffered saline for after thirty minutes of contact time with the solution. The lens care solution will also have a transepithelial electrical resistance (TEER) of HCEpiC within a 25% difference or less than phosphate buffered saline in Ohm / cm2 after one hour of contact time with a 3:1 dilution (solution:DMEM), or the ECIS electrode arrays exhibit a 25% difference or less than phosphate buffered saline in Ohm after one hour of contact time with a 1:1 dilution (solution:DMEM).

The invention relates to a positioning and marking method for embryonic-period primordial germ cells (PGCs), in particular to a bastard halibut embryonic-period primordial germ cell tracking and positioning method. The bastard halibut embryonic-period primordial germ cell tracking and positioning method includes the steps of fixing collected various periods of embryo samples of the bastard halibuts by a 4% PFA solution; using a PBS (phosphate buffer saline) solution with 50% of deionized formamide to preserve the embryo samples at the temperature of -20 DEG C, and subjecting the fixed and preserved embryo samples to oolemma removing, gradient methanol dewatering and rewatering; after rewatering, washing the various periods of embryo samples with PBS buffering liquid without RNA ( ribonucleic acid) enzyme, pre-hybridizing at the temperature of 62-65 DEG C for 2-4 hours; after hybridization, adding a hybridization solution with bastard halibut RNA probes into the various periods of embryo samples subjected to pre-hybridization for hybridizing overnight at the temperature of 62-65 DEG C; after hybridization, subjecting the various periods of embryo samples to washing, antibody incubation and rewashing, keeping away from light, and developing colors to achieve marking for tracking and positioning of the embryonic-period primordial germ cells of the bastard halibuts. The bastard halibut embryonic-period primordial germ cell tracking and positioning method has the advantages that the problems that yolks and oolemma of the samples hybridized in situ conventionally are difficult to strip and a background color is too deep after color developing detection are solved, and operation steps are simplified.

The invention provides a method of disposing kitchen waste and recovering electric power with an air cathode microbial fuel cell, and relates to the method of using the microbial fuel cell to dispose the kitchen waste and recover electric power. The method is used for solving the problems that the existing disposing method of the kitchen waste is low in energy utilization rate, and triggers a secondary pollution easily. The method includes that : firstly, carbon powder is evenly mixed with a polytetrafluoroethylene (PTFE), and the mixture is daubed on a carbon cloth which is heated in a muffle furnace; secondly, high-concentration PTFE is coated on the cloth to heat again; thirdly, then platinum-carbon catalyst is daubed, and a platinized carbon cloth cathode is acquired; fourthly, a carbon brush anode is in preparation; fifthly, the carbon brush anode, a resistance and the air cathode are in connection through a wire, and a cell reactor is assembled; sixth, leachate of food is pretreated; seventh, phosphate buffered saline (PBS) buffer solution is in preparation, and the leachate is diluted; eighth, the leachate is diluted to be neutral; ninth, reactor water is injected into a reactor to dispose the kitchen waste and recover the electric power. The efficiency of disposing the kitchen waste is good, and chemical oxygen demand (COD) removal rate reaches to 86.4%. The method is mainly used for the disposing and utilization of the kitchen waste.

The invention discloses a method for preparing polyethylene glycol hydrogel for orthotopic injection. The method comprises the following steps of: preparing a multi-mercapto linear polyethylene glycol polyether ester by polycondensation with polyethylene glycol and thiomalic acid as raw materials and rare earth trifluoromethanesulfonate as a catalyst; preparing a double-bond linear polyethylene glycol polyether ester by polycondensation with polyethylene glycol and maleic anhydride as starting raw materials and rare earth trifluoromethanesulfonate as a catalyst; and dissolving multi-mercapto linear polyethylene glycol polyether ester and multiple double-bond linear polyethylene glycol polyether esters in a phosphate buffered saline (PBS) buffer solution respectively, quickly mixing the two solutions uniformly and standing the mixed solution to obtain the polyethylene glycol hydrogel for orthotopic injection. The method is simple; conditions are easy to control, so that the method is suitable for industrial production. The invention also discloses the polyethylene glycol hydrogel for orthotopic injection, which is degradable.

The invention discloses a tissue preserving fluid. The tissue preserving fluid is composed of, by concentration, 1.0-2.5%w / v of poloamer, 1.0-2.5%w / v of polyvinylpyrrolidone, 0.2-1.0%w / v of glucose, 15-40%w / v of compound amino acid injection, 5-30%w / v of propylene glycol, 10-40%w / v of PBS (phosphate buffer saline) vitamin E, 0.1-1.5%w / v of vitamin C and 0.1-1.0%w / v of aqueous solvent for injection. Due to the fact of containing no DMSO (dimethylsulfoxide) or protein, the tissue preserving fluid can avoid toxicity produced due to DMSO reverse infusion as well as safety worries of serum and proteins on clinical application, thereby being high in safety.

The invention relates to a method for preparing an NGAL (Neutrophil Gelatinase Associated Lipocalin) optical excitation chemiluminescence detection kit. The method comprises the following steps: activating a luminous microsphere, namely activating the luminous microsphere through prepared carbodiimide and Sulfo-NHS solutions in a PBS (Phosphate Buffer Saline) buffer solution, wherein the luminous microsphere is a carboxyl modified luminous microsphere, and the luminous microsphere is coated with dimethylthiophene, anthracene and rubrene and carried with an europium chelate; coupling the luminous microsphere with an anti-NGAL antibody, namely selecting the carboxyl modified luminous microsphere, carrying out mixing reaction on the anti-NGAL monoclonal antibody and the activated carboxyl modified luminous microsphere to couple the anti-NGAL antibody to the luminous microsphere, and adding freshly prepared carbodiimide at the same time while mixing the anti-NGAL antibody and the activated luminous microsphere; labeling the anti-NGAL antibody through biotin; and labeling a photosensitive microsphere through avidin. The invention also relates to preparation and use methods of the NGAL optical excitation chemiluminescence detection kit. The methods disclosed by the invention solve the problems that the sensitivity is low and the detection is easily interfered by the environment in a detection method in the prior art.

The invention discloses a manufacturing method of a biological tooth root bracket material. The method comprises the following steps of: flushing teeth with phosphate buffered saline (PBS) in a sterile state for three times; removing dental crown parts by grinding with a carborundum disc, and keeping tooth root parts; pulling pulp tissues out of the tooth roots and repeatedly flushing the inside of root canals with physiological saline; gradually expanding the inside of teeth with a dental expander and repeatedly flushing the inside of the root canals with 5 to 17 percent of ethylene diamine tetraacetic acid (EDTA) solution; grinding outer side tissues of the tooth roots by grinding with a dental turbine and constructing a biological tooth root profile as required so as to obtain a bracket with a specific shape; preserving the teeth in the PBS and treating in an ultrasonic oscillator for 3 to 8 times; performing stepped demineralization on a dentine with EDTA with different concentrations in a magnetic stirrer with the rotating speed of between 100 and 500 revolutions per minute so as to obtain a dentine substrate; and preserving the dentine substrate in double-antibody-containing PBS. The biological tooth root bracket material has a tooth root profile, the thickness of 1mm to 3mm, the length of 1cm to 2.5cm and certain tooth inducing capability, comprises a large number of proteins and factors related to the manufacturing of teeth, can release the proteins and factors continuously, can better solve the problem of induction micro-environment, and contributes to application to tooth socket intra-alveolar orthotopic transplantation.

A method for separation the collagen from the various animal tissues is disclosed for preparing collagen solution and product using the same. The porcine tissues are processed to have proper form and size for acid-treatment. The acid-treatment is repeated with pepsin to separate type I or II collagens. The separated collagen is salt-treated for fractionation and ethanol-treated for obtaining 5˜10% of collagen from the initial tissue weight. The prepared tissues are processed for separating collagen through the collagen separating process. The separated collagen is processed for preparing product. The method for preparing product is comprised: treating a collagen solution having a predetermined concentration under a neutral condition at a low temperature, followed by overnight treatment at a temperature of 30 to 35° C.; concentrating collagen by centrifugation; and dissolving the thus-concentrated collagen in refrigerated weakly-acidic solvent or phosphate buffered saline (PBS), thereby preparing collagen having a concentration of 1 to 5 mg / mL.

The invention relates to an antirabies virus IgG (Immunoglobulin G) antibody kit for dogs. In the kit, an enzyme label plate is coated with anti-rabies virus monoclonal antibodies in advance, wherein a coating buffer solution is 0.05M of carbonate buffer solution with pH of 9.6, and the coating amount is 0.1-1ug per hole; 1-10% of BSA (Bull Serum Albumin) or skimmed milk in percentage by mass concentration is used as a blocking buffer; rabies virus purified antigens are coated after blocking, wherein the coating amount is 0.1-1ug per hole; 0.01mol / L PBS (Phosphate-Buffered Saline) with pH 7.2-7.4 containing 0.1-10% of BSA and 0.01-0.05% of NaN3 in percentage by mass concentration is used as a sample diluent; a horse radish peroxidase-rabbit anti-rabies IgG enzyme conjugate is used as an enzyme conjugate; 0.01mol / L PBS with pH 7.2-7.4 containing tween-20 with volume concentration of 0.05% is used as a washing concentrate; an enzyme substrate A solution is a 3,3'-5,5'-tetramethyl benzidine solution, and an enzyme substrate B solution is a hydrogen peroxide solution; a 1 mol / L H2SO4 solution is adopted as a stop solution; and a positive control and a negative control are arranged in the kit. With 100% of specificity and 1:640 of sensitivity, the kit is used for the immune effect evaluation of experimental dogs, pet dogs and common dogs which are inoculated with rabies vaccines.

The invention relates to a preparation method of APP (Actinobacillus Pleuropneumoniae) OMVs (Outer Membrane Vesicles) and a vaccine of the APP OMVs, and belongs to the technical field of biology. The preparation method comprises the steps of culturing APP shope strains in vitro by using a culture medium which is in iron ion limit, obtaining acellular cultural supernatant after carrying out centrifugation and 0.22-[mu]m filtration treatment, and preparing the OMVs released by germs through ultracentrifugation, wherein the observation through a transmission electron microscope shows that the diameter of most OMVs is 50 to 100 nm, the OMVs are used as subunit vaccines to carry out secondary intranasal immunization on a mouse, the weight of the OMV immune mouse is increased for a long time, and the visual forms of lungs have no obvious difference from a PBS (Phosphate Buffer Saline) immune group. Meanwhile, an experiment shows that the OMVs are efficient immune stimulants, not only can high-level IgG (Immunoglobulin G) be stimulated to be generated by mouse sera, but also high-level IgA (Immunoglobulin A) can be generated in mouse lungs, mucosal immunity of the mouse lungs is effectively stimulated, and a better application prospect of using the OMVs as the subunit vaccines is expressed.